



Emerging Trends In Computational Biosensors: Challenges And Future Directions

Abhishek Futane¹, Vigneswaran Narayanamurthy^{2,3*}, Vigneswara Rao Gannapathy², Pramod Jadhav⁴, Kok Swee Leong⁵

¹Fakulti Kejuruteraan Elektronik dan Kejuruteraan Komputer, Universiti Teknikal Malaysia Melaka, Hang Tuah Jaya, 76100 Durian Tunggal, Melaka, Malaysia

²Advance Sensors and Embedded Systems (ASECs), Centre for Telecommunication Research & Innovation, Fakulti Teknologi Kejuruteraan Elektrik Dan Elektronik, Universiti Teknikal Malaysia Melaka, Hang Tuah Jaya, 76100 Durian Tunggal, Melaka, Malaysia

^{2,3*}Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, India

⁴Faculty of Civil Engineering Technology, Universiti Malaysia Pahang (UMP) Lebuhraya Tun Razak, 26300 Gambang, Kuantan, Pahang, Malaysia

⁵Advance Sensors and Embedded Systems (ASECs), Centre for Telecommunication Research & Innovation, Fakulti Kejuruteraan Elektronik dan Kejuruteraan Komputer, Universiti Teknikal Malaysia Melaka, Hang Tuah Jaya, 76100 Durian Tunggal, Melaka, Malaysia

***Corresponding Author:** Vigneswaran Narayanamurthy

^{*}Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, India, Email: vigneswaran@utem.edu.my

Abstract

Biosensors are powerful analytical devices that detect and quantify target analytes in a sample. Due to their high selectivity and sensitivity, enzymes, proteins, antibodies, peptides, and whole cells are commonly used as sensing elements in biosensors. However, the design and optimization of biosensors can be challenging due to the complexity of these biomolecules and their interactions with target analytes. In recent years, computational methods have emerged as powerful tools for designing and optimizing biosensors, enabling researchers to predict the behavior of biomolecules and their interactions with target analytes. Computational fluid mechanics can aid in the design of microfluidic systems for biosensing applications. In contrast, molecular dynamic simulation, molecular docking, quantum mechanics, and virtual screening methods can be used to predict the behavior of biomolecules at the atomic level and study the binding kinetics and thermodynamics of interactions. This paper critically discusses the use of computational methods in biosensors, focusing on enzyme-based, protein-based, antibody-based, peptide-based, and whole-cell-based biosensors. We also review using computational fluid mechanics, molecular dynamic simulation, molecular docking, quantum mechanics, and virtual screening methods in biosensor design and optimization. Additionally, we discuss the applications of these computational methods and biosensors in healthcare, environmental monitoring, food safety, biodefense, and security. Combining computational biosensors and computational methods offers tremendous potential for developing advanced biosensors with enhanced sensitivity, specificity, and accuracy. However, challenges remain, such as the need for more accurate models and the integration of experimental and computational approaches. We conclude by discussing the prospects and challenges of computational biosensors and methods, highlighting the need for further research to drive innovation and improve human health and well-being.

Keywords: Computational biosensors, Computational methods, Target analytes

1.0 Introduction

Biosensors are analytical devices that detect and quantify the presence of target analytes in a sample by exploiting biological recognition events (1). Due to their high selectivity and sensitivity towards target analytes, enzymes, antibodies, peptides, and whole cells are commonly used as sensing elements in biosensors (2). However, the design and optimization of biosensors can be challenging due to the complexity of these biomolecules and their interactions with target analytes. The capacity to detect and discriminate nucleic acid sequences is essential for a wide range of applications, such as high throughput screening, mutation tracking for disease emergence, monitoring genetically modified organisms (GMOs), molecular computing, biometrics fingerprinting, and various genotype-associated studies (3). Traditional sensor systems are multistep platforms that frequently rely heavily on post-processing performed off-platform to determine the success of detection or categorize the biomolecule discovered. Modern high-throughput systems interpret molecular recognition events using conventional or silicon-based computing (4). De-noising and processing sensor output signals are tasks that sophisticated bioinformatics algorithms perform (5). For portable, lab-on-chip systems, this method can be error-prone and difficult to integrate into emerging microsystem technologies (6). Portable computational biosensor systems would

be especially helpful for monitoring and diagnostic purposes in resource-constrained environments or circumstances, such as those found in developing countries and in military medical support applications (7).

Recently, research scientists and medical organizations have switched to adopting affordable biosensors to control human biological processes and to evaluate accurate health diagnoses. To conduct their research, scientists and medical professionals require cost-effective, safe methods to ensure public safety and provide patients with personalized health alternatives. The use of biosensors is one simple way to implement such a solution. Biomedical studies of diagnosis are becoming more important in the modern medical field (8). It is now possible to identify diseases and monitor the body's response to treatment due to advancements in biosensor technology. Modern medical gadgets are capable of a wide range of low-cost and improved feasible factors in emerging sensor technology (9)

Computational methods have emerged as powerful tools for designing and optimizing biosensors, enabling researchers to predict the behavior of biomolecules and their interactions with target analytes (10). Computational fluid mechanics can aid in the design of microfluidic systems for biosensing applications (11). In contrast, molecular dynamic simulation, molecular docking, quantum mechanics, and virtual screening methods can be used to predict the behavior of biomolecules at the atomic level and study the binding kinetics and thermodynamics of interactions (12). This combination of computational biosensors and computational methods offers tremendous potential for developing advanced biosensors with enhanced sensitivity, specificity, and accuracy. In this context, We highlight their applications in the design and optimization of biosensors, focusing on enzyme-based, protein-based, antibody-based, peptide-based, and whole-cell-based biosensors with computer methods used in biosensor improvement.

2.0 Computational biosensors

The roots of computational biosensors can be found in the young discipline of biocomputing (3). Significant improvements in chemical and biochemical information processing have been made because of increased biocomputing research; this success is partly attributable to the inherent high specificity and selectivity of biological molecules. Additionally, the general compatibility of biomolecules permits the close assembly of various biomolecules within cascading networks that can carry out a variety of reactions (13). Bioreceptor, transducers, and signal processing systems are the three fundamental parts of a biosensor (14). Enzymes, proteins, peptides, antibodies, nucleic acids, and aptamers are receptors binding to their specified objective (4). Biochemical signals from the target interaction with its bioreceptor are converted to a detectable electrical signal using transducers. A signal processing system then measures the amplified electrical signal and converts the measurable signal. (15) Perhaps the most promising application of biocomputing with analytical systems is in the field of biomedicine (16,17). A new class of computationally intelligent biosensors that can accept input signals and systematically compute and analyze them could be produced using biocomputing and logic operations. For the system to sense and respond, the biosensors' signal output can also be coupled to signal-responsive components or procedures (18). Such "intelligent" biosensors would have several advantages over conventional biosensors, which typically only accept a single input and output a signal that needs further processing and analyzing by a skilled operator to yield meaningful results. Significant and exciting developments in intelligent computational biosensors have resulted from successfully integrating biocomputing principles with biosensing. A thorough review involves multiple target analyses using computational biosensors




Fig 1 Computations biosensors

2.1 Enzymes-based computational biosensor

Enzymes are very beneficial in constructing POC biosensing platforms because enzymes are highly stable and simple to control (19). Enzyme-based computational biosensors are a type of biosensor that uses enzymes as the sensing element and integrate computational methods to analyze and interpret the data generated by the biosensor. Enzymes can catalyze specific reactions that produce a measurable signal, and computational methods can analyze this signal to provide

quantitative measurements of the target analyte. There are several examples of enzyme-based computational biosensors, including the use of machine learning algorithms to analyze data from glucose biosensors for the monitoring of diabetes and the use of neural networks to analyze data from lactate biosensors for the monitoring of athletes (20).

Amperometric biosensors use enzymes to catalyze reactions that produce an electrical current, which can be measured to provide quantitative measurements of the target analyte (21). For enzyme-based biosensors, electrochemical transducers are most frequently employed. Glucose and urea biosensors are the most popular enzyme-based biosensors. For in vitro real-time monitoring of glucose in the brain, Cordeiro et al. developed and characterized W-Au-based amperometric enzyme-based glucose biosensors. Their research showed that an advanced W-Au-based sensor could track changes in brain glucose in response to pertinent pharmacological tests. Computational methods can be used to analyze the data and improve the accuracy and sensitivity of the biosensor (4). Lactate biosensors are used to measure lactate levels in biological samples, such as blood or sweat, which can be an important parameter for monitoring exercise performance, assessing tissue oxygenation, or diagnosing certain medical conditions (22,23).

Alcohol biosensors are used to measure alcohol concentration in breath, blood, or other biological samples, which is important for monitoring blood alcohol content (BAC) in forensic and law enforcement settings (24),16). Phenol biosensors monitor phenol and phenolic compounds in environmental, industrial, and clinical samples (26). Glutamate biosensors are used for measuring glutamate levels in biological samples. The resulting current can be measured and analyzed using a computer-based system to provide real-time monitoring of glutamate levels in neuroscience research or clinical diagnostics (27). Potentiometric biosensors use enzymes to catalyze reactions that produce a change in voltage, which can be measured to provide quantitative measurements of the target analyte. Glucose biosensors are used to monitor blood glucose levels in diabetic patients, while cholinesterase biosensors are used to detect organophosphate pesticides and nerve agents (28). Urea biosensors measure urea levels in biological fluids, which are important indicators of renal function and metabolic disorders (29). Nanoparticles were used by Uygun et al. to create a highly stable potentiometric urea biosensor. Their developed sensor had a 30 s response time and a 0.77 M detection limit, respectively (30). Enzyme-based computational potentiometric biosensors offer high specificity and sensitivity for target analytes. It can provide real-time monitoring and quantitative analysis of various biomolecules and analytes when integrated with computational methods.

Optical biosensors use enzymes to catalyze reactions that produce a change in fluorescence, absorbance, or reflectance, which can be measured to provide quantitative measurements of the target analyte. Horseradish peroxidase (HRP)-based optical biosensors are used to detect hydrogen peroxide, -galactosidase, glucose oxidase (GOx), and alkaline phosphatase. HRP is an enzyme that catalyzes the oxidation of substrates using hydrogen peroxide (H₂O₂) (31). β -galactosidase is an enzyme that catalyzes the hydrolysis of β -galactosides, such as lactose, to produce galactose and glucose(32). GOx is an enzyme that catalyzes the oxidation of glucose to produce gluconic acid and hydrogen peroxide (H₂O₂) (33). Alkaline phosphatase is an enzyme that catalyzes the hydrolysis of phosphate groups from a wide range of substrates (34). The resulting signal can be detected and quantified using an optical detector and analyzed using a computer-based system.

Piezoelectric biosensors use the piezoelectric effect to generate an electrical signal in response to mechanical stress or pressure. Enzymes can be immobilized on the piezoelectric surface, where they catalyze the conversion of the target analyte, leading to a change in mass or surface stress, which is then detected as a change in the piezoelectric signal. Lipase-based biosensors for detecting triglycerides in food and biological samples (35), protease-based biosensors for detecting proteolytic activity in food and environmental samples(36), choline oxidase-based biosensors for detecting choline in biological samples(37), lactate oxidase-based biosensors for detecting lactate in blood and other biological fluids(22). These biosensors offer high sensitivity and specificity, fast response time, and can be used for a wide range of applications in healthcare, environmental monitoring, food safety, and more. The biosensor design and performance may vary depending on the specific analyte and enzyme used and the overall biosensor configuration. Enzyme-based computational biosensors offer a powerful tool for detecting and analyzing specific biomolecules with high accuracy and reliability and have the potential to revolutionize many areas of research and industry, including medicine, biotechnology, and environmental science.




Fig 2 Enzymes-based computational biosensor (38)

2.2 Protein-based computational biosensor

Protein-based computational biosensors use proteins as the sensing element and integrate computational methods to analyze and interpret the data generated by the biosensor (39). These biosensors combine the high sensitivity and specificity of protein-based biosensors with the computational power of modern computing to produce highly accurate and reliable measurements. In a protein-based computational biosensor, the protein sensing element is immobilized on a transducer surface and interacts with the target analyte to produce a measurable signal (40). The signal is then processed using computational methods, such as machine learning algorithms, to analyze the data and provide quantitative measurements of the target analyte. Protein-based computational biosensors have several advantages over traditional biosensors, including improved accuracy, reduced noise, and the ability to detect multiple analytes simultaneously. There are several types of protein-based computational biosensors.

Protein-DNA interactions play a crucial role in various biological processes. Computational methods are employed to study the binding kinetics, thermodynamics, and stability of protein-DNA complexes. Protein-DNA biosensors leverage these interactions to detect and quantify target analytes, such as DNA sequences or DNA-binding proteins (41). Nanomaterials such as Au nanoparticles, graphene based assemblies, carbon nanotubes and magnetic nanoparticles are the most widely used nanomaterials for biosensing. Preparation mechanisms and surface engineering are the driving forces for a biosensing suitability of these entities (42). Protein nanoparticle-based materials provide increased sensitivity and specificity for electrochemical and other biosensor configurations (43). Computational methods assist in the design and optimization of protein-nanoparticle hybrid biosensors. These biosensors utilize the unique properties of nanoparticles, such as enhanced sensitivity and signal amplification, in combination with protein receptors to detect and quantify target analytes. Machine learning-based biosensors use machine learning algorithms to analyze data from protein-based biosensors and provide quantitative measurements of the target analyte. Machine learning algorithms can identify patterns and trends in the data, improving the accuracy and reliability of the biosensor (39). Neural networks can model complex relationships between the data and the target analyte, improving the sensitivity and specificity of the biosensor. Neural network-based biosensors use neural networks to analyze data from protein-based biosensors and provide quantitative measurements of the target analyte (44). Graphene-based biosensors use graphene as the transducer surface and proteins as the sensing element to detect and measure specific biomolecules. The high conductivity and sensitivity of graphene, combined with the specificity of proteins, make graphene-based biosensors highly sensitive and accurate (45). Microfluidic biosensors use microfluidic devices to manipulate and analyze samples, allowing for highly accurate and precise measurements of specific biomolecules. Proteins can be immobilized on the microfluidic channels to act as the sensing element, and computational methods can be used to analyze the data generated by the biosensor (46). The fluorescence intensity can be measured using computational methods to provide quantitative measurements of the target analyte. Fluorescent biosensors use fluorescent proteins as the sensing element to detect and measure specific biomolecules (47).




Fig 3. Protein-based biosensor (48)

2.3 Peptide-based computational biosensor

Peptide-based computational biosensors use peptides as the sensing element and integrate computational methods to analyze and interpret the data generated by the biosensor (49). Peptides are short chains of amino acids that can bind to specific target molecules with high affinity and specificity, making them ideal for sensing elements in biosensors (50). There are several examples of peptide-based computational biosensors, including using peptide aptamers to detect small molecules and using peptides to detect proteins and viruses. Aptamer-based biosensors use peptides, or peptide aptamers,

as the sensing element to detect target analytes such as small molecules, proteins, and viruses (51). The peptides are designed to bind specifically to the target analyte, and computational methods can be used to optimize the design of the peptides for maximum binding affinity and specificity (52). The peptides are designed to bind specifically to the surface of the microorganisms, and computational methods can be used to optimize the design of the peptides for maximum binding affinity and specificity. The effectiveness of antimicrobial peptides (AMPs) as potential new therapeutic agents against pathogenic microorganisms has been emphasized (53). AMPs are a part of the immune systems of many different types of organisms, including bacteria (54), mammals (55), plants (56), and insects (57). In 2009, Zampa and colleagues (58) conducted the first study demonstrating the label-free detection of microbial cells by a biosensor using AMPs. Dermaseptin-01 AMPs immobilized in electroactive nanostructured layered films allowed for detecting the *Leishmania chagasi* parasite at a detection limit of 103 cells mL⁻¹. Cyclic voltammetry measurements were made, demonstrating the viability of using unlabelled AMPs in biosensors. Such a strategy has a number of advantages because it typically makes the detection process simpler (59).

Successful peptide-based sensing platforms must carefully choose, synthesise, and characterize the bioreceptor to maximize target interaction and surface coverage and ensure high-affinity, selective, and repeatable recognition. Proteases serve as indicators for numerous other uses. For example, proteases made by bacteria can be used to detect their presence. That particular (synthetic) peptide sequences may be used as recognition receptors in quantitative/qualitatively detecting and monitoring various bacteria. Therefore, peptide-based biosensors might represent a quick and affordable system for defense against pathogenic bacteria. In light of this, Eissa and Zourob (60) developed a method for the multiplexed detection of *Listeria monocytogenes* (LOD of 9 CFU/mL) and *Staphylococcus aureus* (LOD of 3 CFU/mL) by utilizing the proteolytic activities of the proteases produced by these two bacteria to hydrolyze a synthetic peptide sequence used as substrate. Peptide nucleic acid-based biosensors use peptide nucleic acids (PNAs) as the sensing element to detect specific nucleic acid sequences. PNAs are synthetic molecules that mimic the structure of DNA and RNA and can be designed to bind specifically to target nucleic acid sequences. PNAs can be used in hybridization applications with tighter binding and higher specificity, leading to faster and easier procedures. It can also be used in affinity electrophoresis and biosensor procedures to detect complementary strands or mismatches (60). Computational methods can be used to optimize the design of the PNAs for maximum binding affinity and specificity.

2.4 Antibody-based computational biosensor

Antibody-based computational biosensors use antibodies as the sensing element and integrate computational methods to analyze and interpret the data generated by the biosensor. Antibodies are proteins produced by the immune system in response to a specific antigen, and it can bind to their target antigens with high specificity and affinity, making them ideal for use as sensing elements in biosensors (61). In an antibody-based computational biosensor, the antibody sensing element is immobilized on a transducer surface and interacts with the target analyte to produce a measurable signal. The signal is then processed using computational methods, such as machine learning algorithms, to analyze the data and provide quantitative measurements of the target analyte (62). Antibody-based computational biosensors have several advantages over traditional biosensors, including improved sensitivity, specificity, and stability. There are several examples of antibody-based computational biosensors, including monoclonal antibodies to detect specific proteins or pathogens and recombinant antibodies to detect small molecules or other targets.

In a sandwich assay, two antibodies are used, one as a capture antibody and the other as a detection antibody. The capture antibody is immobilized on the biosensor surface. It binds to the target analyte, while the detection antibody is labeled with a signal-generating molecule and binds to a different site on the target analyte. ELISA-based analysis can detect foodborne pathogens, such as *C. fetus* (63) and *E. coli* O157:H7 (64), using digital signals interpreted by a computer-aided readout. In a competitive assay, a labeled target analyte competes with the unlabeled target analyte for binding to the immobilized antibody. The amount of labeled analyte that attaches to the antibody is inversely proportional to the concentration of the unlabeled analyte in the sample. A highly sensitive competitive Single molecule array was created by scientists for the detection of small molecules. We demonstrate that the sensitivity of the competitive Single molecule arrays is roughly 50 times greater than that of the traditional ELISA (65). This improved analytical sensitivity makes it possible to measure small molecules at previously impossible concentrations and provides access to previously unobservable biological phenomena.

Antibody-fragment-based biosensors use antibody fragments, such as single-chain variable (scFvs) or Fab fragments, as the sensing element (66). The antibody fragments are smaller and more stable than full-length antibodies and can be designed using computational methods to optimize their binding affinity and specificity. This biosensor is envisioned as a small, portable device that can be produced in large quantities, minimized for development into a handheld point-of-care device. It is useful in remote or developing areas without easy access to sophisticated laboratory facilities (67). Aptamer-antibody hybrid biosensors use a hybrid molecule consisting of an antibody and an aptamer as the sensing element. Amyloid beta-peptide can be used as a biomarker of Alzheimer's disease, and a glassy carbon electrode was modified with carboxyl graphene, BSA, and an aptamer probe. A linear response range was observed with a detection limit of 100 pM (68). An antibody-aptamer assay detects C-reactive protein with a detection limit of 0.4 mgmL⁻¹ (69). The aptamer is designed to bind to the target analyte with high affinity and specificity, while the antibody provides a

second binding site for the analyte. Computational methods can be used to optimize the design of the aptamer and the antibody for maximum binding affinity and specificity and to analyze the data generated by the biosensor.




Fig 4. Antibody-based computational biosensor (70)

2.5 Nucleic acid-based computational biosensor

Nucleic acid-based computational biosensors use nucleic acids, such as DNA or RNA, as the sensing element and integrate computational methods to analyze and interpret the data generated by the biosensor. Nucleic acids can selectively recognize and bind to specific target molecules, making them ideal for sensing in biosensors (3). In a nucleic acid-based computational biosensor, the nucleic acid sensing element is designed to recognize and bind to the target analyte, producing a measurable signal that a transducer can detect. Computational methods, such as DNA computing or machine learning algorithms, can be used to analyze the data generated by the biosensor and provide quantitative measurements of the target analyte (4). There are several examples of nucleic acid-based computational biosensors.

Aptamer-based biosensors rely on the specific binding between an aptamer and its target molecule to detect and quantify the presence of the target molecule (52). Computational methods can be used in various stages of developing aptamer-based biosensors, including design, optimization, and analysis. Computational methods are used in aptamer-based biosensors to design and optimize aptamer sequences with high binding affinity and specificity to the target molecule (71). These methods consider the structural and chemical properties of the target molecule, as well as the binding affinity and specificity of the aptamer. Molecular docking simulations can be used to predict the compulsory mode and energy of an aptamer-target complex; structural analysis can be used to analyze the 3D structure of the aptamer-target complex, and signal processing and data analysis can be used to process and analyze the signals generated by biosensors (72). DNA microarrays use thousands of DNA probes to detect the presence and abundance of specific DNA or RNA sequences in a sample. The probes are attached to a solid support, such as a glass slide, and the hybridization of the target nucleic acids to the probes is detected (73). PCR-based biosensors use PCR amplification to detect and quantify specific DNA or RNA sequences in a sample. The PCR amplification products of human coronaviruses are detected (74). CRISPR-based biosensors use the CRISPR-Cas system, a natural defense mechanism in bacteria against foreign DNA. The system can be programmed to recognize specific DNA or RNA sequences, and the binding of the target nucleic acids to the CRISPR-Cas system is detected. Scientists discussed the CRISPR/Cas system for detecting various pathogenic bacteria like *L. monocytogenes*, *M. tuberculosis*, *Methicillin-resistant S. aureus*, *Salmonella*, *E. coli*, *P. aeruginosa*, and *A. baumannii*. (75). Hybridization-based biosensors use the hybridization of complementary nucleic acid strands as the recognition element to detect target analytes. The complementary strands are designed to specifically bind to the target analyte and trigger a change in the electrical or optical properties of the biosensor. Biosensors have become increasingly popular due to their physicochemical stability and ability to discriminate between organism strains. DNA biosensors (Geno sensors) are used for their physicochemical stability and suitability to distinguish different organism strains (76).

2.6 Whole-cell-based computational biosensor

A whole cell-based computational biosensor uses intact cells as the sensing element and integrates computational methods to analyze and interpret the data generated by the biosensor. Cells possess and express a series of molecular recognition

elements, such as receptors, ion channels, and enzymes, which are usually sensitive to their corresponding analytes (77). Whole cell-based biosensors can continuously monitor and analyze various physiological parameters under external stimulation, such as changes to the cell's metabolism, impedance, and action potential (78). This has led to these biosensors becoming widely applicable to many fields in biomedicine, such as cellular physiological analysis, pharmaceutical evaluation, and medical diagnosis. Whole cells can be genetically engineered to produce a specific response in the presence of a target analyte, making them ideal for use as the sensing element in biosensors (78). In a whole cell-based computational biosensor, the cells are genetically engineered to produce a specific reporter gene, such as green fluorescent protein (GFP), in response to the presence of the target analyte. The amount of reporter genes produced by the cells can be quantified and analyzed using computational methods to measure the target analyte (59) quantitatively. The genetic mutation in drug targets, such as G protein-coupled receptors (GPCRs), and changes in their response to medications is a current research goal of precision medicine. For instance, a novel label-free, whole-cell-based biosensor was developed to characterize GPCR-mediated drug responses in lymphoblastoid cell lines (LCLs) (79). This suggests whole-cell-based biosensors may be applied in precision medicine as a cellular model system for studying GPCR pharmacology in vitro. The field of micronutrients is another area where whole-cell sensors are used. Riboflavin is a vital vitamin for human health, and a deficiency can cause serious conditions like cancer, cataracts, and metabolism disorders (58). A key objective in disease diagnosis is the swift and precise detection of pathogens. Since patient blood and urine samples must first be precultured enough for their detection, conventional microbiological methods can take several days to weeks. For the precise and direct detection of bacteria, a novel approach based on whole-cell biosensors was created that did not require this time-consuming culture step (81). Such targets can be monitored using computational methods for quantitative and qualitative measurements. Whole cell-based biosensors have special advantages that have developed in part due to their ease of use and quick application to provide results for diagnosing various diseases. As a result, whole-cell biosensor-based biomedical diagnosis techniques exhibit great promise and potential.




Fig 5 Whole-cell-based computational biosensor (82)

Table 1 Computational biosensors applications

| Biosensor Type | Description | Application | References |
|---------------------|--|--|------------|
| Nucleic acid-based | Use nucleic acids (adenine, thymine, cytosine, and guanine) to detect specific sequences or mutations. | Detection of genetic disorders, identification of infectious agents | (83,84) |
| Microfluidics-based | Use microfluidic technology (Chips, lab-on chips, droplets) to detect analytes | Point-of-care diagnostics, monitoring of drug levels in the blood | (85,86) |
| Optical based | Use light to detect changes in analytes. | Measuring oxygen saturation, monitoring protein-protein interactions | (9,87) |
| Whole cell-based | Use living cells to detect changes in their environment, often through genetic engineering | Detection of toxins in the environment, monitoring of cell metabolism | (88,89) |
| Protein-based | Use proteins (Insulin, Collagen, Myosin) to detect analytes | Detection of cancer biomarkers, tracking of infectious diseases | (90,91) |
| Antibody-based | Use antibodies (Alemtuzumab, Adalimumab) to detect analytes | Detection of infectious diseases, monitoring of autoimmune disorders | (92,93) |
| Enzyme-based | Use enzymes (RNA/RNA polymerase, Proteases) to detect and quantify analytes | Glucose monitoring in diabetes, lactate measurement in sports medicine | (94,95) |
| Peptide-based | Use peptides (Oxytocin, Glucagon, Angiotensin) to detect analytes | Detection of toxins and pathogens in food and water | (96,97) |

3.0 Computational methods for improvement of biosensors

In recent years, computational methods have emerged as valuable tools for designing and optimizing biosensors (10). These computational approaches enable researchers to predict and understand the behavior of biomolecules and the interactions between biomolecules and target analytes. By leveraging computational methods, scientists can accelerate the development and enhance the performance of biosensors (3,4). Integrating computational methods with experimental approaches in biosensing research holds great promise. It enables researchers to make informed decisions in the design and development of biosensors, saving time and resources by identifying the most promising candidates for experimental validation. Through a comprehensive understanding of the computational methods utilized in biosensing, we aim to showcase the potential of these approaches to drive innovation, improve biosensor performance, and contribute to advancements in human health and well-being.




Fig.6 Computational methods used in biosensor development.

3.1 Computational fluid dynamics

Computational fluid dynamics (CFD) used to study the behavior of fluids, such as liquids and gases, in motion. CFD is a powerful tool in biosensing, as it can provide valuable insights into the behavior of fluids in microfluidic devices, which are commonly used in biosensing applications with enhanced efficiency and lower operating costs (98). Murthy K S N et al. proposed designing and simulating MEMS microcantilever sensors for identifying *Mycobacterium tuberculosis* from a blood sample. Here researcher used COMSOL Multiphysics to define the structural mechanics of microcantilever. (99). Komen et al. (81) created a microfluidic system that can expose cancer cells to a medication concentration profile that mimics that found in vivo and quantify the effectiveness on-chip. A transparent membrane was used to divide the drug-dosing channel from the cell culture chamber in this system, protecting the drug from shear stresses and enabling label-free growth quantification. Scientists experimented with cell exposure and confirmed that the blood concentrations determined in vivo were followed.

To achieve the right cell responses, optimizing the physical features of nanoparticles (NPs), such as their size and shape, is important. Nanoparticles (NPs) have drawn interest for their potential application as drug delivery systems (100). The impact of gold nanoparticles on IDE systems for impedance-based biosensing approaches is demonstrated through COMSOL Multiphysics simulations. Additionally, the best design parameters to provide the highest sensitivity can be discovered using these simulations. (101). To replicate the essential characteristics of complicated drug and nanoparticle transport inside a tumor microenvironment, Kwak and colleagues (102) created a tumor-microenvironment-on-chip. Scientists gained more in-depth knowledge of the dynamic transport behavior of NPs through the combination of computational simulations and experimental tests, and researcher concluded that NPs should be designed with consideration for their interactions with the tumor microenvironment. Scientists investigated a report of a study biosensor based on silicon into an effect on the dimensions of conductance design and simulation nanowire surface with molecular DNA for sensitivity. By leveraging computational methods, scientists can accelerate the development and enhance the performance of biosensors used COMSOL Multiphysics software to provide interaction within the DNA. researcher computed surface nanowire charge using the Poisson equation with Boltzmann statistics. (103)

Researchers discovered A photonic crystal fiber (PCF) biosensor based on surface plasmon resonance (SPR) to obtain maximum sensitivity for detecting unknown analytes. Sensing performance is numerically investigated by the finite element method (FEM) based on commercially available tools COMSOL Multiphysics. The amplitude sensitivity of the proposed sensor is 442.11 RIU^{-1} with sensor resolution 1.66×10^{-5} . (104) To optimize the exposure period for autophagy,

a biological mechanism where proteins are digested and recycled to provide another source of energy to cells, Karakas and coworkers (105) designed a microfluidic device for screening individual cancer cells (Figure 7a). Researchers were able to save time and resources during experimental tests by using this numerical investigation to establish the minimal exposure duration necessary to guarantee the success of the studies. On the other hand, Zhang et al. (106) investigated the change in the blood and buffer inlet flow rates affected the ability of circulating tumor cells to be separated in a microfluidic chip and modified the operating parameters to improve separation effectiveness.

Jun-Shan et al. (107) developed a microfluidic chip with micropillar arrays for 3D cell culture, and using numerical simulations, the space between micropillars was optimized, allowing nutrients in the medium to diffuse quickly into the chamber and cell metabolites to diffuse out of the chamber on time. This method was another way to increase a device's accuracy. Chen and colleagues conducted a similar investigation using micropillars (108). In this instance, the authors looked at pillars with square, elliptical, and circular cross-sections arranged in aligned and staggered patterns. The latter situation results in fluid flowing through the array's Centre and surrounding the pillars, the researchers discovered through numerical simulations. These findings prompted the study team to examine this strategy since the fluid is more evenly dispersed throughout the device in staggered patterns. To simulate mechanical interactions between flow and particles (cells) for cells-on-a-chip systems, Zhang et al. (109) developed a two-way Euler/Lagrange multiphase model. Using three alternative designs, the authors investigated the effect of using varying cell densities, intake flow velocities, and inlet cell numbers. The findings demonstrated that greater cell densities were found in locations with lower strain rates and at lower inflow velocities (10 and 20 m/s). However, scientists discovered that some cells could get to the outlet at a speed of 40 m/s while others could not. Microfluidic devices are small-scale systems that can manipulate and analyze fluids at the microliter or nanoliter scale. CFD simulations can predict the behavior of fluids in microfluidic devices, optimize the design of microfluidic devices, and study the transport of analytes in microfluidic devices. CFD is a valuable tool in biosensing, as it can provide insights into the behavior of fluids and help to optimize their design for improved performance.

Table.2 CFD Applications

| Disease | Biosensor Type | CFD Application | Reported accuracy (%) | References |
|------------------------|---------------------------|---|-----------------------|------------|
| Cancer | Electrochemical | Simulation of fluid flow and mass transport to optimize electrode design and maximize sensitivity | 90-95 | (110) |
| Diabetes | Optical | Modeling of microfluidic channels to improve the accuracy and reliability of glucose measurements | +/- 5 | (111) |
| Cardiovascular disease | Electrochemical | Investigation of flow patterns and mixing in microchannels to enhance the detection of cardiac biomarkers | 93 | (112) |
| Infectious diseases | Surface plasmon resonance | Optimization of surface functionalization and fluid flow to improve detection limits and reduce false positives | 92-99 | (113) |
| Alzheimer's disease | Electrochemical | Investigation of transport phenomena to optimize electrode design and enhance the sensitivity of detection | Not reported | (114) |
| Parkinson's disease | Optical | Modeling of fluid flow and mass transport in microfluidic channels to improve detection limits | Not reported | (115) |
| Tuberculosis | Electrochemical | Simulation of flow and transport to improve sensor sensitivity and reduce false positives | 94-98 | (116) |
| Hepatitis B | Surface plasmon resonance | Investigation of surface chemistry and flow conditions to optimize detection limits | Not reported | (117) |
| HIV/AIDS | Optical | Modeling of microfluidic channels to enhance specificity and sensitivity of detection | 95-100 | (118) |
| Malaria | Electrochemical | Simulation of transport phenomena to optimize electrode design and enhance the sensitivity of detection | 90-98 | (119) |

3.2 Molecular dynamic simulation

Molecular dynamics (MD) simulation is a powerful tool in biosensing, as it can provide valuable insights into the interactions between biomolecules and biosensors. By simulating the behavior of biomolecules at the atomic level, MD simulations can help to understand the binding mechanisms between the biomolecules and the biosensor, as well as predict the performance of the biosensor under different conditions (120). Scientists are trying to understand how proteins and other biomolecules react with each other on an atomic level. A biomolecule's atomic-level structure is incredibly useful and often yields significant insight into how the biomolecule functions. However, because the atoms in a biomolecule are constantly in motion, the dynamics of the individual molecules affect both their intramolecular connections and molecular function. The capacity to observe these biomolecules in action, to disturb them at the atomic level, and to observe how

biomolecule react depends on the dynamic or biomolecules involved. Observing the motions of individual atoms and disturbing them in a desirable way is challenging. This problem can be minimized using an atomic-level computer simulation of the necessary biomolecules.

In recent years, molecular dynamics (MD) simulations have significantly increased their influence on molecular biology and drug development. These simulations completely capture the atomic level details and extremely fine temporal resolutions of the behavior of proteins and other biomolecules. The appeal of biomolecular modeling to experimentalists has expanded due to significant advancements in simulation speed, accuracy, and accessibility, as well as the abundance of experimental structure data. The understanding of the workings of proteins and other biomolecules, the discovery of the structural underpinnings of disease, and the design and optimization of small molecules, peptides, and proteins have all benefited from simulations. (121)

MD simulation can be performed by using several program packages, such as CHARMM (122), GROMACS (123), NAMD (124), AMBER (125), LAMMPS (126), and GROMOS (127). Typically, GROMACS computes the MD parameters 3-10 times more rapidly than other programs. NAMD can efficiently run on parallel machines to study large molecules. Scientists describe the first method for predicting the three-dimensional structures of single-stranded DNA needed for aptamer applications. By combining 2D and 3D structural tools like Mfold, assemble 2, Chimera, VMD, and Molecular Dynamics (MD) simulations, the method accurately predicts the representative resolved structures contained in the Nucleic Acid Database (NDB) and Protein Data Bank (PDB) databases. Specifically, scientists create similar 3D ssRNA models, convert the 3D ssRNA models into ssDNA 3D structures, and then explicitly build ssDNA secondary structure from sequence. Finally, we refine the resultant ssDNA 3D structures by energy minimization. (128).

MD simulations are a valuable tool in biosensing as it can provide insights into the behavior of biomolecules at a level of detail that is not possible through experimental methods alone. MD simulations can be used to investigate the binding of a ligand to a protein target in a biosensor and to study the interactions between a biosensor and a lipid bilayer in biological membranes.

3.3 Molecular docking

Molecular docking used to predict small molecules or ligands' binding modes and affinities to a receptor or target protein. This method generates multiple ligand and protein conformations and then computationally indicates their optimal orientation and interactions at the binding site (129). Molecular docking involves two steps: ligand preparation and receptor preparation. Ligand preparation involves removing solvent molecules and optimizing their conformation, while receptor preparation involves removing any ligands or co-crystallized molecules and optimizing their conformation. Docking simulation involves generating multiple conformations of the ligand and protein and evaluating their binding affinity and energy. Analysis and visualization are used to identify the ligand's most likely compulsory mode and affinity to the receptor (130).

The behavior of tiny molecules at the binding site of a target protein is investigated by molecular docking methods. Conventional methods like NMR (Nuclear magnetic resonance, X-ray crystallography and cryomicroscopy) determine a huge amount of protein structure. Hence, molecular docking is increasingly used as an emerging tool in biomedical engineering (131). A few researchers used the AutoDock Vina to conduct a molecular docking analysis to examine the binding mechanism between the ZEN and aptamers. The secondary structure of the linear ssDNA was predicted using the Mfold web service. The Vienna output format file was utilized to create the aptamer's three-dimensional (3-D) structure. Using the ChemBioDraw Ultra14.0 program, the ZEN molecule's structure was drawn with the correct two-dimensional (2-D) orientation, and the drawing was reviewed for flaws. Using the software ChemBio3D Ultra 14.0, ZEN's energy was reduced. The docking input files were created using the AutoDockTools 1.5.6 package. Unless otherwise stated, the default settings were used for Vina docking. (132)

In another study, peptide aptamer was used for the detection of L-arginine. From the protein sequences of four species, *Homo sapiens*, *Mus musculus*, *Rattus norvegicus*, and *Sus scrofa*, eight-mer peptide aptamers were isolated. The UniProt database yielded 29,185 protein sequences for the four species. A sliding window of eight amino acids was used to scan the protein sequences, and a total of 2,854,481 peptide fragments were produced. The eight-mer peptides were constructed into -helices using PyMol, and these conformations served as the starting point for the molecular dynamics simulations. Using AutoDock 4.2.6, simulations were run to test the stability of eight-mer peptide and L-Arg complexes (133). Xiongfei Zhao et al. also developed a fluorescent probe DNC for point-of-care detection of Albuminuria. Scientists studied the Albumin-sensing mechanism by molecular docking using the software Autodock. Their work provides a novel design strategy for reducing the interference from urinary fluorescence on the detection result. (134)

Computer-based applications play a crucial role in biosensing by enabling the analysis, interpretation, and management of the vast amounts of data generated by biosensors. Examples include machine learning algorithms to analyze biosensor data, computer simulations to model the behavior of biosensors, and databases to store and retrieve large amounts of data. These applications are essential to developing and implementing biosensing technologies, enabling researchers and

practitioners to analyze, interpret, and manage the complex data generated by biosensors and optimize their performance for a wide range of applications (135,136).

3.4 Quantum mechanics

Quantum mechanics has also been applied to computational biosensing, which involves using computational methods to analyze and interpret biosensor data. Quantum computing, in particular, has the potential to greatly improve the speed and efficiency of computational biosensing by allowing for the processing of large amounts of data and the simulation of complex biochemical processes (3).

One example of using quantum mechanics in computational biosensing is the development of quantum algorithms for analyzing biological data. Quantum algorithms are designed to run on quantum computers, which use quantum mechanical phenomena to process information fundamentally differently than classical computers. Quantum algorithms have been developed for various biosensing applications, including protein folding prediction, DNA sequencing, and drug discovery (137). Another example is using quantum mechanics to simulate biological processes, such as protein-protein interactions or enzyme catalysis. Manufacturing these processes using classical computers is often computationally intensive and time-consuming, but quantum computing can greatly accelerate these simulations. This could lead to the discovery of new drugs or the development of more efficient biosensors (138). Juliana Khecheto and coworkers developed a label-free capacitive design interface using quantum mechanics to diagnose dengue viral infection. Researchers used DFT Hamiltonian analysis for requiring minimal manipulation of patient samples to detect DENV. The minimal need for manipulating biological samples is attributed to the reagent-less nature of electrochemical capacitive assays. This capacitive method can potentially compete with traditional serological laboratory assays, with the advantage of being inexpensive and compact, especially when compared with ELISA methods which require labeled secondary antibodies, or expensive NAAT assays. (139)

Quantum mechanics has also been applied to the design of biosensors with improved sensitivity and specificity. For example, quantum coherence effects have been used to develop biosensors that can detect the presence of single molecules with high accuracy. These biosensors use quantum mechanical phenomena to detect changes in the electronic properties of the sensing material caused by the binding of a target molecule (140). Overall, the application of quantum mechanics to computational biosensing has the potential to greatly improve the speed, accuracy, and efficiency of biosensing. However, the development of quantum computing and quantum algorithms is still in its early stages, and much research is needed to realize their potential in biosensing fully.

3.5 Virtual screening

Virtual screening has ability to predict small molecules' binding affinity to a target protein or biomolecule (141). It can be applied to developing biosensors by predicting the binding of small molecule probes to specific biomolecules of interest (142). In biosensors, small molecule probes are often used to detect and measure the presence of specific biomolecules, such as proteins or nucleic acids. Virtual screening can identify small molecule probes with high binding affinity and selectivity for the target biomolecule (143). This can significantly reduce the time and cost required for experimental screening of large compound libraries. Virtual screening in biosensors is the development of small molecule probes for protein kinase activity (144). Protein kinases are enzymes that play a critical role in cell signaling and are often dysregulated in diseases such as cancer (145). Small molecule probes that selectively bind to specific protein kinases can be used to monitor their activity in cells and tissues. Virtual screening can also identify small molecule probes to detect pathogens or toxins (146). Virtual screening can identify small molecule inhibitors of bacterial toxins such as cholera toxin and anthrax toxin, which could be used as probes for detecting these toxins in food or water samples. Virtual screening is a powerful tool for the development of biosensors, as it allows for the rapid identification of small molecule probes with high binding affinity and selectivity for specific biomolecules of interest.

4.0 Critical discussion

Combining computational biosensors and computational methods such as fluid mechanics, molecular dynamics, molecular docking, quantum mechanics, and virtual screening offers numerous opportunities to develop advanced biosensors with enhanced sensitivity, specificity, and accuracy. Enzymes, proteins, antibodies, peptides, and whole cells are commonly used as sensing elements in biosensors, and computational methods can help optimize their performance by predicting their interactions with target analytes and optimizing their binding affinity and selectivity. Computational fluid mechanics can aid in designing microfluidic systems for biosensing applications, indicating the flow behavior of fluids, and optimizing the flow patterns to enhance analyte transport and detection efficiency (11). Molecular dynamics simulations and quantum mechanics calculations can be used to predict the behavior of biomolecules at the atomic level and to study the binding kinetics and thermodynamics of enzyme-substrate, protein-ligand, and antibody-antigen interactions (147). Virtual screening methods can be used to screen large databases of compounds and identify potential ligands with high affinity and specificity for a given target. However, there are also limitations to these computational methods. Molecular dynamics simulations are limited by the size of the systems that can be studied and the accuracy of the force fields used. Virtual screening methods rely on accurate structural models of the target and may miss important conformational changes that occur upon ligand binding (146). The accuracy of molecular docking methods is also limited by the accuracy of the scoring functions used to evaluate ligand binding (148). Therefore, integrating multiple computational methods and using

hybrid approaches can help overcome some of these limitations and improve the accuracy and reliability of biosensor design and optimization. Combining computational biosensors and computational methods is a promising approach to developing advanced biosensors for various applications, including healthcare, environmental monitoring, and food safety (149–151). However, further research and development are needed to optimize these methods, overcome their limitations, and demonstrate their effectiveness in real-world applications.

5.0 Conclusion and future prospective

The development of biosensors that can detect multiple targets simultaneously or targets with high sensitivity and specificity in complex biological matrices is an area of active research. Furthermore, integrating biosensors with other technologies, such as microfluidics and wearable devices, is expected to enable new applications in personalized medicine and point-of-care testing areas (152,153). Furthermore, integrating different computational methods and developing hybrid approaches that combine multiple methods are expected to enable the study of complex phenomena that cannot be studied using a single method alone. Integrating molecular dynamics simulations with quantum mechanics calculations can provide a more accurate description of electronic structure and chemical reactions. In contrast, integrating virtual screening with molecular docking can enable the identification of novel drug candidates with high specificity and affinity (154).

The combination of computational biosensors and computational methods, including enzyme, protein, antibody, peptide, and whole cell-based biosensors, along with computational fluid mechanics, molecular dynamic simulation, molecular docking, quantum mechanics, and virtual screening, offers tremendous potential for the development of advanced biosensors with enhanced sensitivity, specificity, and accuracy. These computational methods can optimize sensing elements' performance by predicting their interactions with target analytes and optimizing their binding affinity and selectivity. Additionally, computational fluid mechanics can aid in designing microfluidic systems for biosensing applications. In contrast, molecular dynamics simulations and quantum mechanics calculations can be used to predict the behavior of biomolecules at the atomic level and study the binding kinetics and thermodynamics of interactions (155). However, there are limitations to these computational methods, and the accuracy and reliability of biosensor design and optimization can be improved by integrating multiple computational methods and using hybrid approaches (10). Further research and development are needed to optimize these methods, overcome their limitations, and demonstrate their effectiveness in real-world applications.

Looking towards the future, the continued development and refinement of these methods are expected to further advance our understanding of molecular systems and their interactions, accelerate the growth of new drugs, materials, and technologies, and enable the development of biosensors with increasingly enhanced sensitivity and specificity (156,157). Furthermore, integrating these methods with emerging technologies such as machine learning and artificial intelligence is expected to improve the accuracy and predictive power of biosensors and computational methods, enabling the development of more complex and sophisticated biosensing systems (158). Advances in computational methods, such as machine learning and artificial intelligence, are expected to improve biosensor design, optimization accuracy, and efficiency. Additionally, the development of novel materials, such as nanomaterials and biomimetic materials, is expected to enhance the sensitivity and specificity of biosensors (159). The future of computational methods is bright, and these technologies are poised to play an increasingly important role in a wide range of fields, from healthcare to environmental monitoring to materials design. The continued development and refinement of these methods are expected to advance our understanding of molecular systems and their interactions and accelerate the development of new drugs, materials, and technologies.

6.0 Conflict of interest

There are no conflicts of interest to declare.

7.0 Acknowledgement

This study was sponsored by “UTeM Zamalah Scheme”, Universiti Teknikal Malaysia, Melaka.

8.0 References

1. Bhalla N, Jolly P, Formisano N, Estrela P. Introduction to biosensors. Estrela P, editor. *Essays Biochem.* 2016 Jun 30;60(1):1–8.
2. Morales MA, Halpern JM. Guide to Selecting a Biorecognition Element for Biosensors. *Bioconjug Chem.* 2018 Oct 17;29(10):3231–9.
3. May EE, Harper JC, Brozik SM. Computational Biosensors: Molecules, Algorithms, and Detection Platforms. In: Suzuki J, Nakano T, Moore MJ, editors. *Modeling, Methodologies and Tools for Molecular and Nano-scale Communications* [Internet]. Cham: Springer International Publishing; 2017 [cited 2023 Apr 7]. p. 541–77. (*Modeling and Optimization in Science and Technologies*; vol. 9). Available from: http://link.springer.com/10.1007/978-3-319-50688-3_23
4. Naresh Varnakavi, Lee N. A Review on Biosensors and Recent Development of Nanostructured Materials-Enabled Biosensors. *Sensors.* 2021 Feb 5;21(4):1109.

5. Liu Y, Lin J. A general-purpose signal processing algorithm for biological profiles using only first-order derivative information. *BMC Bioinformatics*. 2019 Dec;20(1):611.
6. Ducrée J. Efficient Development of Integrated Lab-On-A-Chip Systems Featuring Operational Robustness and Manufacturability. *Micromachines*. 2019 Dec 17;10(12):886.
7. Myung NV, Jung S, Kim J. Application of Low-Cost, Easy-to-Use, Portable Biosensor Systems for Diagnosing Bladder Dysfunctions. *Int Neurourol J*. 2019 Mar;23(1):86–7.
8. Rahman MM, Ghoshal UC, Ragunath K, Jenkins G, Rahman M, Edwards C, et al. Biomedical research in developing countries: Opportunities, methods, and challenges. *Indian J Gastroenterol*. 2020 Jun;39(3):292–302.
9. Haleem A, Javaid M, Singh RP, Suman R, Rab S. Biosensors applications in medical field: A brief review. *Sens Int*. 2021;2:100100.
10. Khoshbin Z, Housaindokht MR, Izadyar M, Bozorgmehr MR, Verdian A. Recent advances in computational methods for biosensor design. *Biotechnol Bioeng*. 2021 Feb;118(2):555–78.
11. Low WS, Kadri NA, Wan Abas WABB. Computational Fluid Dynamics Modelling of Microfluidic Channel for Dielectrophoretic BioMEMS Application. *Sci World J*. 2014;2014:1–11.
12. Aghajani J, Farnia P, Farnia P, Ghanavi J, Velayati AA. Molecular Dynamic Simulations and Molecular Docking as a Potential Way for Designed New Inhibitor Drug without Resistance. *Tanaffos*. 2022 Jan;21(1):1–14.
13. Nagamune T. Biomolecular engineering for nanobio/bionanotechnology. *Nano Converg*. 2017 Dec;4(1):9.
14. Tetyana P, Morgan Shumbula P, Njengele-Tetyana Z. Biosensors: Design, Development and Applications. In: Ameen S, Shaheer Akhtar M, Shin HS, editors. *Nanopores* [Internet]. IntechOpen; 2021 [cited 2022 Jul 11]. Available from: <https://www.intechopen.com/books/nanopores/biosensors-design-development-and-applications>
15. Tereshchenko A, Bechelany M, Viter R, Khranovskyy V, Smyntyna V, Starodub N, et al. Optical biosensors based on ZnO nanostructures: advantages and perspectives. A review. *Sens Actuators B Chem*. 2016 Jun;229:664–77.
16. Tregubov AA, Nikitin PI, Nikitin MP. Advanced Smart Nanomaterials with Integrated Logic-Gating and Biocomputing: Dawn of Theranostic Nanorobots. *Chem Rev*. 2018 Oct 24;118(20):10294–348.
17. Roquero DM, Katz E. “Smart” alginate hydrogels in biosensing, bioactuation and biocomputing: State-of-the-art and perspectives. *Sens Actuators Rep*. 2022 Nov;4:100095.
18. Wu X, Bai X, Ma Y, Wei J, Peng J, Shi K, et al. Construction of Multiple Switchable Sensors and Logic Gates Based on Carboxylated Multi-Walled Carbon Nanotubes/Poly(N,N-Diethylacrylamide). *Sensors*. 2018 Oct 8;18(10):3358.
19. Staiano M, Pennacchio A, Varriale A, Capo A, Majoli A, Capacchione C, et al. Enzymes as Sensors. In: *Methods in Enzymology* [Internet]. Elsevier; 2017 [cited 2022 Jul 28]. p. 115–31. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0076687917300411>
20. Jin X, Cai A, Xu T, Zhang X. Artificial intelligence biosensors for continuous glucose monitoring. *Interdiscip Mater*. 2023 Mar;2(2):290–307.
21. Bollella P, Gorton L. Enzyme based amperometric biosensors. *Curr Opin Electrochem*. 2018 Aug;10:157–73.
22. Rathee K, Dhull V, Dhull R, Singh S. Biosensors based on electrochemical lactate detection: A comprehensive review. *Biochem Biophys Rep*. 2016 Mar;5:35–54.
23. Xuan X, Pérez-Ràfols C, Chen C, Cuartero M, Crespo GA. Lactate Biosensing for Reliable On-Body Sweat Analysis. *ACS Sens*. 2021 Jul 23;6(7):2763–71.
24. Campbell AS, Kim J, Wang J. Wearable Electrochemical Alcohol Biosensors. *Curr Opin Electrochem*. 2018 Aug;10:126–35.
25. Alpat Ş, Telefoncu A. Development of an Alcohol Dehydrogenase Biosensor for Ethanol Determination with Toluidine Blue O Covalently Attached to a Cellulose Acetate Modified Electrode. *Sensors*. 2010 Jan 21;10(1):748–64.
26. Mazhari BBZ, Agsar D, Prasad MVNA. Development of Paper Biosensor for the Detection of Phenol from Industrial Effluents Using Bioconjugate of Tyr-AuNps Mediated by Novel Isolate *Streptomyces taurus* DBZ39. *J Nanomater*. 2017;2017:1–8.
27. Ganesana M, Trikantopoulos E, Maniar Y, Lee ST, Venton BJ. Development of a novel micro biosensor for in vivo monitoring of glutamate release in the brain. *Biosens Bioelectron*. 2019 Apr 1;130:103–9.
28. Nguyen HH, Lee SH, Lee UJ, Fermin CD, Kim M. Immobilized Enzymes in Biosensor Applications. *Mater Basel Switz*. 2019 Jan 2;12(1):121.
29. Kim J, Sung GY, Park M. Efficient Portable Urea Biosensor Based on Urease Immobilized Membrane for Monitoring of Physiological Fluids. *Biomedicines*. 2020 Dec 11;8(12):596.
30. Öndeş B, Akpınar F, Uygun M, Muti M, Aktaş Uygün D. High stability potentiometric urea biosensor based on enzyme attached nanoparticles. *Microchem J*. 2021 Jan;160:105667.
31. Krainer FW, Glieder A. An updated view on horseradish peroxidases: recombinant production and biotechnological applications. *Appl Microbiol Biotechnol*. 2015 Feb;99(4):1611–25.
32. Saqib S, Akram A, Halim SA, Tassaduq R. Sources of β -galactosidase and its applications in food industry. *3 Biotech*. 2017 May;7(1):79.
33. Yoo EH, Lee SY. Glucose Biosensors: An Overview of Use in Clinical Practice. *Sensors*. 2010 May 4;10(5):4558–76.
34. Balbaied T, Moore E. Overview of Optical and Electrochemical Alkaline Phosphatase (ALP) Biosensors: Recent Approaches in Cells Culture Techniques. *Biosensors*. 2019 Aug 23;9(3):102.

35. Rosli NH, Mohd Zain Z, Ahmad NM. Lipase Based Biosensors for Triglyceride Determination. Abdul Amir HF, Korsunsky AM, Guo Z, editors. MATEC Web Conf. 2016;59:01012.
36. Webb AJ, Kelwick R, Doenhoff MJ, Kylilis N, MacDonald JT, Wen KY, et al. A protease-based biosensor for the detection of schistosome cercariae. *Sci Rep*. 2016 Apr 19;6(1):24725.
37. Uwaya GE, Fayemi OE. Enhanced Electrocatalytic Detection of Choline Based on CNTs and Metal Oxide Nanomaterials. *Molecules*. 2021 Oct 28;26(21):6512.
38. Kurup CP, Ahmed MU. Nanozymes towards Personalized Diagnostics: A Recent Progress in Biosensing. *Biosensors*. 2023 Apr 5;13(4):461.
39. Guo Z, Johnston WA, Whitfield J, Walden P, Cui Z, Wijker E, et al. Generalizable Protein Biosensors Based on Synthetic Switch Modules. *J Am Chem Soc*. 2019 May 22;141(20):8128–35.
40. Silva SM, Li M, Mendes AX, Moulton SE. Reagentless protein-based electrochemical biosensors. *The Analyst*. 2023;148(9):1930–8.
41. Ahmad S, Keskin O, Sarai A, Nussinov R. Protein-DNA interactions: structural, thermodynamic and clustering patterns of conserved residues in DNA-binding proteins. *Nucleic Acids Res*. 2008 Oct;36(18):5922–32.
42. Malik P, Gupta R, Malik V, Ameta RK. Emerging nanomaterials for improved biosensing. *Meas Sens*. 2021 Aug;16:100050.
43. Shankar KR, Ameta RK, Singh M. Preparation of BSA nanoparticles using aqueous urea at T = 308.15, 313.15 and 318.15 K as a function of temperature. *J Mol Liq*. 2016 Apr;216:808–13.
44. Srinivasan B, Tung S. Development and Applications of Portable Biosensors. *SLAS Technol*. 2015 Aug;20(4):365–89.
45. Bai Y, Xu T, Zhang X. Graphene-Based Biosensors for Detection of Biomarkers. *Micromachines*. 2020 Jan 3;11(1):60.
46. Kulkarni MB, Ayachit NH, Aminabhavi TM. Biosensors and Microfluidic Biosensors: From Fabrication to Application. *Biosensors*. 2022 Jul 20;12(7):543.
47. Sargazi S, Fatima I, Hassan Kiani M, Mohammadzadeh V, Arshad R, Bilal M, et al. Fluorescent-based nanosensors for selective detection of a wide range of biological macromolecules: A comprehensive review. *Int J Biol Macromol*. 2022 May;206:115–47.
48. Alexandrov K, Vickers CE. In vivo protein-based biosensors: seeing metabolism in real time. *Trends Biotechnol*. 2023 Jan;41(1):19–26.
49. Xiao X, Kuang Z, Slocik JM, Tadepalli S, Brothers M, Kim S, et al. Advancing Peptide-Based Biorecognition Elements for Biosensors Using *in-Silico* Evolution. *ACS Sens*. 2018 May 25;3(5):1024–31.
50. Sfragano PS, Moro G, Polo F, Palchetti I. The Role of Peptides in the Design of Electrochemical Biosensors for Clinical Diagnostics. *Biosensors*. 2021 Jul 23;11(8):246.
51. Futane A, Narayanamurthy V, Jadhav P, Srinivasan A. Aptamer-based rapid diagnosis for point-of-care application. *Microfluid Nanofluidics*. 2023 Feb;27(2):15.
52. Ning Y, Hu J, Lu F. Aptamers used for biosensors and targeted therapy. *Biomed Pharmacother*. 2020 Dec;132:110902.
53. Piotrowska U, Sobczak M, Oledzka E. Current state of a dual behaviour of antimicrobial peptides-Therapeutic agents and promising delivery vectors. *Chem Biol Drug Des*. 2017 Dec;90(6):1079–93.
54. Zacharof MP, Lovitt RW. Bacteriocins Produced by Lactic Acid Bacteria a Review Article. *APCBEE Procedia*. 2012;2:50–6.
55. Zasloff M. Antimicrobial peptides of multicellular organisms. *Nature*. 2002 Jan;415(6870):389–95.
56. Tam J, Wang S, Wong K, Tan W. Antimicrobial Peptides from Plants. *Pharmaceuticals*. 2015 Nov 16;8(4):711–57.
57. Montalbán-López M, Sánchez-Hidalgo M, Cebrián R, Maqueda M. Discovering the Bacterial Circular Proteins: Bacteriocins, Cyanobactins, and Pilins. *J Biol Chem*. 2012 Aug;287(32):27007–13.
58. Zampa MF, Araújo IMS, Costa V, Nery Costa CH, Santos JR, Zucolotto V, et al. Leishmanicidal Activity and Immobilization of dermasseptin 01 antimicrobial peptides in ultrathin films for nanomedicine applications. *Nanomedicine Nanotechnol Biol Med*. 2009 Sep;5(3):352–8.
59. Pardoux É, Boturyn D, Roupioz Y. Antimicrobial Peptides as Probes in Biosensors Detecting Whole Bacteria: A Review. *Molecules*. 2020 Apr 24;25(8):1998.
60. Eissa S, Zourob M. Ultrasensitive peptide-based multiplexed electrochemical biosensor for the simultaneous detection of *Listeria monocytogenes* and *Staphylococcus aureus*. *Microchim Acta*. 2020 Sep;187(9):486.
61. Sharma S, Byrne H, O’Kennedy RJ. Antibodies and antibody-derived analytical biosensors. Estrela P, editor. *Essays Biochem*. 2016 Jun 30;60(1):9–18.
62. Schackart KE, Yoon JY. Machine Learning Enhances the Performance of Bioreceptor-Free Biosensors. *Sensors*. 2021 Aug 17;21(16):5519.
63. Brooks BW, Devenish J, Lutze-Wallace CL, Milnes D, Robertson RH, Berlie-Surujballi G. Evaluation of a monoclonal antibody-based enzyme-linked immunosorbent assay for detection of *Campylobacter fetus* in bovine preputial washing and vaginal mucus samples. *Vet Microbiol*. 2004 Oct;103(1–2):77–84.
64. Kerr P, Chart H, Finlay D, Pollock DA, Mackie DP, Ball HJ. Development of a monoclonal sandwich ELISA for the detection of animal and human *Escherichia coli* O157 strains. *J Appl Microbiol*. 2001 Apr;90(4):543–9.
65. Wang X, Cohen L, Wang J, Walt DR. Competitive Immunoassays for the Detection of Small Molecules Using Single Molecule Arrays. *J Am Chem Soc*. 2018 Dec 26;140(51):18132–9.

66. Saerens D, Huang L, Bonroy K, Muyldermans S. Antibody Fragments as Probe in Biosensor Development. *Sensors*. 2008 Aug 8;8(8):4669–86.
67. Ymeti A, Subramaniam V, Beumer TA, Kanger JS. An ultrasensitive Young interferometer handheld sensor for rapid virus detection. *Expert Rev Med Devices*. 2007 Jul;4(4):447–54.
68. Mukherjee M, Manonmani HK, Bhatt P. Aptamer as capture agent in enzyme-linked apta-sorbent assay (ELASA) for ultrasensitive detection of Aflatoxin B1. *Toxicol*. 2018 Dec;156:28–33.
69. Shatunova EA, Korolev MA, Omelchenko VO, Kurochkina YD, Davydova AS, Venyaminova AG, et al. Aptamers for Proteins Associated with Rheumatic Diseases: Progress, Challenges, and Prospects of Diagnostic and Therapeutic Applications. *Biomedicines*. 2020 Nov 22;8(11):527.
70. Choi JR. Development of Point-of-Care Biosensors for COVID-19. *Front Chem*. 2020 May 27;8:517.
71. Han K, Liang Z, Zhou N. Design Strategies for Aptamer-Based Biosensors. *Sensors*. 2010 May 4;10(5):4541–57.
72. Buglak AA, Samokhvalov AV, Zherdev AV, Dzantiev BB. Methods and Applications of In Silico Aptamer Design and Modeling. *Int J Mol Sci*. 2020 Nov 10;21(22):8420.
73. Cagnin S, Caraballo M, Guiducci C, Martini P, Ross M, Santaana M, et al. Overview of electrochemical DNA biosensors: new approaches to detect the expression of life. *Sensors*. 2009;9(4):3122–48.
74. Demeke Teklemariam A, Samaddar M, Alharbi MG, Al-Hindi RR, Bhunia AK. Biosensor and molecular-based methods for the detection of human coronaviruses: A review. *Mol Cell Probes*. 2020 Dec;54:101662.
75. Chakraborty J, Chaudhary AA, Khan SUD, Rudayni HA, Rahaman SM, Sarkar H. CRISPR/Cas-Based Biosensor As a New Age Detection Method for Pathogenic Bacteria. *ACS Omega*. 2022 Nov 8;7(44):39562–73.
76. Teles F, Fonseca L. Trends in DNA biosensors. *Talanta*. 2008 Dec 15;77(2):606–23.
77. Cao Y, Zhang B, Zhu Z, Xin X, Wu H, Chen B. Microfluidic Based Whole-Cell Biosensors for Simultaneously On-Site Monitoring of Multiple Environmental Contaminants. *Front Bioeng Biotechnol*. 2021 Mar 9;9:622108.
78. Gui Q, Lawson T, Shan S, Yan L, Liu Y. The Application of Whole Cell-Based Biosensors for Use in Environmental Analysis and in Medical Diagnostics. *Sensors*. 2017 Jul 13;17(7):1623.
79. Hillger JM, Schoop J, Boomsma DI, Eline Slagboom P, IJzerman AP, Heitman LH. Whole-cell biosensor for label-free detection of GPCR-mediated drug responses in personal cell lines. *Biosens Bioelectron*. 2015 Dec;74:233–42.
80. Powers HJ. Riboflavin (vitamin B-2) and health. *Am J Clin Nutr*. 2003 Jun;77(6):1352–60.
81. Aliakbar Ahovan Z, Hashemi A, De Plano LM, Gholipourmalekabadi M, Seifalian A. Bacteriophage Based Biosensors: Trends, Outcomes and Challenges. *Nanomater Basel Switz*. 2020 Mar 11;10(3):501.
82. Mohammadi S, Nikkhah M, Hosseinkhani S. Investigation of the effects of carbon-based nanomaterials on A53T alpha-synuclein aggregation using a whole-cell recombinant biosensor. *Int J Nanomedicine*. 2017 Dec;Volume 12:8831–40.
83. Chua A, Yean CY, Ravichandran M, Lim B, Lalitha P. A rapid DNA biosensor for the molecular diagnosis of infectious disease. *Biosens Bioelectron*. 2011 May;26(9):3825–31.
84. Hua Y, Ma J, Li D, Wang R. DNA-Based Biosensors for the Biochemical Analysis: A Review. *Biosensors*. 2022 Mar 20;12(3):183.
85. Costa BMDC, Griveau S, d'Orlye F, Bedioui F, Da Silva JAF, Varenne A. Microchip electrophoresis and electrochemical detection: A review on a growing synergistic implementation. *Electrochimica Acta*. 2021 Sep;391:138928.
86. Bahadır EB, Sezgintürk MK. A review on impedimetric biosensors. *Artif Cells Nanomedicine Biotechnol*. 2016 Jan 2;44(1):248–62.
87. Mohankumar P, Ajayan J, Mohanraj T, Yasodharan R. Recent developments in biosensors for healthcare and biomedical applications: A review. *Measurement*. 2021 Jan;167:108293.
88. Moraskie M, Roshid MHO, O'Connor G, Dikici E, Zingg JM, Deo S, et al. Microbial whole-cell biosensors: Current applications, challenges, and future perspectives. *Biosens Bioelectron*. 2021 Nov;191:113359.
89. Mirza Z, Karim S. Nanoparticles-based drug delivery and gene therapy for breast cancer: Recent advancements and future challenges. *Semin Cancer Biol*. 2021 Feb;69:226–37.
90. Misawa N, Osaki T, Takeuchi S. Membrane protein-based biosensors. *J R Soc Interface*. 2018 Apr;15(141):20170952.
91. Ozbakir HF, Miller ADC, Fishman KB, Martins AF, Kippin TE, Mukherjee A. A Protein-Based Biosensor for Detecting Calcium by Magnetic Resonance Imaging. *ACS Sens*. 2021 Sep 24;6(9):3163–9.
92. Menti C, Henriques J a. P, Missell FP, Roesch-Ely M. Antibody-based magneto-elastic biosensors: potential devices for detection of pathogens and associated toxins. *Appl Microbiol Biotechnol*. 2016 Jul;100(14):6149–63.
93. Álvarez Freile J, Choukrani G, Zimmermann K, Bremer E, Dähne L. Whispering Gallery Modes-based biosensors for real-time monitoring and binding characterization of antibody-based cancer immunotherapeutics. *Sens Actuators B Chem*. 2021 Nov;346:130512.
94. Zhu YC, Mei LP, Ruan YF, Zhang N, Zhao WW, Xu JJ, et al. Enzyme-Based Biosensors and Their Applications. In: *Advances in Enzyme Technology* [Internet]. Elsevier; 2019 [cited 2023 May 23]. p. 201–23. Available from: <https://linkinghub.elsevier.com/retrieve/pii/B978044464114400008X>
95. Jung IY, Kim JS, Choi BR, Lee K, Lee H. Hydrogel Based Biosensors for In Vitro Diagnostics of Biochemicals, Proteins, and Genes. *Adv Healthc Mater*. 2017 Jun;6(12):1601475.
96. Wasilewski T, Neubauer D, Kamysz W, Gębicki J. Recent progress in the development of peptide-based gas biosensors for environmental monitoring. *Case Stud Chem Environ Eng*. 2022 May;5:100197.

97. Liu Q, Wang J, Boyd BJ. Peptide-based biosensors. *Talanta*. 2015 May;136:114–27.
98. Ward K, Fan ZH. Mixing in microfluidic devices and enhancement methods. *J Micromechanics Microengineering*. 2015 Sep 1;25(9):094001.
99. Murthy KSN, Prasad GRK, Saikiran NLNV, Manoj TV. Design and Simulation of MEMS Biosensor for the Detection of Tuberculosis. *Indian J Sci Technol* [Internet]. 2016 Aug 23 [cited 2022 Jul 25];9(31). Available from: <https://indjst.org/articles/design-and-simulation-of-mems-biosensor-for-the-detection-of-tuberculosis>
100. Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on *in vivo* pharmacokinetics and cellular interaction. *Nanomed*. 2016 Mar;11(6):673–92.
101. MacKay S, Hermansen P, Wishart D, Chen J. Simulations of Interdigitated Electrode Interactions with Gold Nanoparticles for Impedance-Based Biosensing Applications. *Sensors*. 2015 Sep 2;15(9):22192–208.
102. Kwak B, Ozcelikkale A, Shin CS, Park K, Han B. Simulation of complex transport of nanoparticles around a tumor using tumor-microenvironment-on-chip. *J Controlled Release*. 2014 Nov;194:157–67.
103. Wesam Al-Mufti M, Hashim U, Rahman MdM, Adam T, Md Arshad MK, Rahim Ruslinda A, et al. Studying Effect Dimensions of Design and Simulation Silicon Nanowire Filed Effect Biosensor. *Appl Mech Mater*. 2015 Apr;754–755:854–8.
104. Hossen MdN, Ferdous Md, Abdul Khalek Md, Chakma S, Paul BK, Ahmed K. Design and analysis of biosensor based on surface plasmon resonance. *Sens Bio-Sens Res*. 2018 Nov;21:1–6.
105. Karakas HE, Kim J, Park J, Oh JM, Choi Y, Gozuacik D, et al. A microfluidic chip for screening individual cancer cells via eavesdropping on autophagy-inducing crosstalk in the stroma niche. *Sci Rep*. 2017 Dec;7(1):2050.
106. Zhang X, Xu X, Ren Y, Yan Y, Wu A. Numerical simulation of circulating tumor cell separation in a dielectrophoresis based Y-Y shaped microfluidic device. *Sep Purif Technol*. 2021 Jan;255:117343.
107. Liu JS, Zhang YY, Wang Z, Deng JY, Ye X, Xue RY, et al. Design and Validation of a Microfluidic Chip with Micropillar Arrays for Three-dimensional Cell Culture. *Chin J Anal Chem*. 2017 Aug;45(8):1109–14.
108. Chen W, Li J, Wan X, Zou X, Qi S, Zhang Y, et al. Design of a microfluidic chip consisting of micropillars and its use for the enrichment of nasopharyngeal cancer cells. *Oncol Lett* [Internet]. 2018 Nov 28 [cited 2022 Jul 29]; Available from: <http://www.spandidos-publications.com/10.3892/ol.2018.9771>
109. Zhang M, Zheng A, Zheng ZC, Wang MZ. Multiphase flow experiment and simulation for cells-on-a-chip devices. *Proc Inst Mech Eng [H]*. 2019 Apr;233(4):432–43.
110. Khanmohammadi A, Aghaie A, Vahedi E, Qazvini A, Ghanei M, Afkhami A, et al. Electrochemical biosensors for the detection of lung cancer biomarkers: A review. *Talanta*. 2020 Jan;206:120251.
111. Luka G, Ahmadi A, Najjaran H, Alocilja E, DeRosa M, Wolthers K, et al. Microfluidics Integrated Biosensors: A Leading Technology towards Lab-on-a-Chip and Sensing Applications. *Sensors*. 2015 Dec 1;15(12):30011–31.
112. Shin SR, Zhang YS, Kim DJ, Manbohi A, Avci H, Silvestri A, et al. Aptamer-Based Microfluidic Electrochemical Biosensor for Monitoring Cell-Secreted Trace Cardiac Biomarkers. *Anal Chem*. 2016 Oct 18;88(20):10019–27.
113. Loya SR, Kawamoto K, Chatwin C, Huser V. Service oriented architecture for clinical decision support: a systematic review and future directions. *J Med Syst*. 2014 Dec;38(12):140.
114. Shui B, Tao D, Florea A, Cheng J, Zhao Q, Gu Y, et al. Biosensors for Alzheimer's disease biomarker detection: A review. *Biochimie*. 2018 Apr;147:13–24.
115. Kujawska M, Bhardwaj SK, Mishra YK, Kaushik A. Using Graphene-Based Biosensors to Detect Dopamine for Efficient Parkinson's Disease Diagnostics. *Biosensors*. 2021 Oct 31;11(11):433.
116. Gupta S, Kakkar V. Recent technological advancements in tuberculosis diagnostics – A review. *Biosens Bioelectron*. 2018 Sep;115:14–29.
117. Yao CY. Biosensors for hepatitis B virus detection. *World J Gastroenterol*. 2014;20(35):12485.
118. Nandi S, Mondal A, Roberts A, Gandhi S. Biosensor platforms for rapid HIV detection. In: *Advances in Clinical Chemistry* [Internet]. Elsevier; 2020 [cited 2023 May 23]. p. 1–34. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0065242320300135>
119. Dutta G. Electrochemical biosensors for rapid detection of malaria. *Mater Sci Energy Technol*. 2020;3:150–8.
120. Gelpi J, Hospital A, Goñi R, Orozco M. Molecular dynamics simulations: advances and applications. *Adv Appl Bioinforma Chem*. 2015 Nov;37.
121. Hollingsworth SA, Dror RO. Molecular Dynamics Simulation for All. *Neuron*. 2018 Sep;99(6):1129–43.
122. Jo S, Cheng X, Lee J, Kim S, Park S, Patel DS, et al. CHARMM-GUI 10 years for biomolecular modeling and simulation. *J Comput Chem*. 2017 Jun 5;38(15):1114–24.
123. Páll S, Zhmurov A, Bauer P, Abraham M, Lundborg M, Gray A, et al. Heterogeneous parallelization and acceleration of molecular dynamics simulations in GROMACS. *J Chem Phys*. 2020 Oct 7;153(13):134110.
124. Phillips JC, Hardy DJ, Maia JDC, Stone JE, Ribeiro JV, Bernardi RC, et al. Scalable molecular dynamics on CPU and GPU architectures with NAMD. *J Chem Phys*. 2020 Jul 28;153(4):044130.
125. Mermelstein DJ, Lin C, Nelson G, Kretsch R, McCammon JA, Walker RC. Fast and flexible gpu accelerated binding free energy calculations within the amber molecular dynamics package. *J Comput Chem*. 2018 Jul 15;39(19):1354–8.
126. Sharma S. Molecular dynamics simulation of nanocomposites using BIOVIA materials studio, lammmps and gromacs. 1st ed. Waltham: Elsevier; 2019.
127. Riniker S. Fixed-Charge Atomistic Force Fields for Molecular Dynamics Simulations in the Condensed Phase: An Overview. *J Chem Inf Model*. 2018 Mar 26;58(3):565–78.

128. Jeddi I, Saiz L. Three-dimensional modeling of single stranded DNA hairpins for aptamer-based biosensors. *Sci Rep*. 2017 Dec;7(1):1178.
129. Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. *Curr Comput Aided Drug Des*. 2011 Jun;7(2):146–57.
130. Al-Karmalawy AA, Dahab MA, Metwaly AM, Elhady SS, Elkaeed EB, Eissa IH, et al. Molecular Docking and Dynamics Simulation Revealed the Potential Inhibitory Activity of ACEIs Against SARS-CoV-2 Targeting the hACE2 Receptor. *Front Chem*. 2021 May 4;9:661230.
131. Pagadala NS, Syed K, Tuszynski J. Software for molecular docking: a review. *Biophys Rev*. 2017 Apr;9(2):91–102.
132. Zhang Y, Lu T, Wang Y, Diao C, Zhou Y, Zhao L, et al. Selection of a DNA Aptamer against Zearalenone and Docking Analysis for Highly Sensitive Rapid Visual Detection with Label-Free Aptasensor. *J Agric Food Chem*. 2018 Nov 14;66(45):12102–10.
133. He Y, Zhou L, Deng L, Feng Z, Cao Z, Yin Y. An electrochemical impedimetric sensing platform based on a peptide aptamer identified by high-throughput molecular docking for sensitive l-arginine detection. *Bioelectrochemistry*. 2021 Feb;137:107634.
134. Zhao X, Zheng W, Qin T, Du X, Lei Y, Lv T, et al. An anti-interference fluorescent probe for point-of-care diagnosis of albuminuria. *Sens Actuators B Chem*. 2022 Jan;351:130980.
135. Cui F, Yue Y, Zhang Y, Zhang Z, Zhou HS. Advancing Biosensors with Machine Learning. *ACS Sens*. 2020 Nov 25;5(11):3346–64.
136. Manickam P, Mariappan SA, Murugesan SM, Hansda S, Kaushik A, Shinde R, et al. Artificial Intelligence (AI) and Internet of Medical Things (IoMT) Assisted Biomedical Systems for Intelligent Healthcare. *Biosensors*. 2022 Jul 25;12(8):562.
137. Bova F, Goldfarb A, Melko RG. Commercial applications of quantum computing. *EPJ Quantum Technol*. 2021 Dec;8(1):2.
138. Arodola OA, Soliman ME. Quantum mechanics implementation in drug-design workflows: does it really help? *Drug Des Devel Ther*. 2017 Aug;Volume 11:2551–64.
139. Cecchetto J, Santos A, Mondini A, Cilli EM, Bueno PR. Serological point-of-care and label-free capacitive diagnosis of dengue virus infection. *Biosens Bioelectron*. 2020 Mar;151:111972.
140. Chalklen T, Jing Q, Kar-Narayan S. Biosensors Based on Mechanical and Electrical Detection Techniques. *Sensors*. 2020 Sep 30;20(19):5605.
141. Park HJ, Park SJ. Virtual Screening for RNA-Interacting Small Molecules. In: Dinman JD, editor. *Biophysical approaches to translational control of gene expression* [Internet]. New York, NY: Springer New York; 2012 [cited 2023 Apr 9]. p. 235–52. Available from: http://link.springer.com/10.1007/978-1-4614-3991-2_12
142. Mehrotra P. Biosensors and their applications – A review. *J Oral Biol Craniofacial Res*. 2016 May;6(2):153–9.
143. Lionta E, Spyrou G, Vassilatis DK, Cournia Z. Structure-based virtual screening for drug discovery: principles, applications and recent advances. *Curr Top Med Chem*. 2014;14(16):1923–38.
144. Gonçalves AM, Pedro AQ, Santos FM, Martins LM, Maia CJ, Queiroz JA, et al. Trends in protein-based biosensor assemblies for drug screening and pharmaceutical kinetic studies. *Mol Basel Switz*. 2014 Aug 18;19(8):12461–85.
145. Paul MK, Mukhopadhyay AK. Tyrosine kinase - Role and significance in Cancer. *Int J Med Sci*. 2004;1(2):101–15.
146. Kumar A, Zhang KYJ. Hierarchical virtual screening approaches in small molecule drug discovery. *Methods San Diego Calif*. 2015 Jan;71:26–37.
147. Salo-Ahen OMH, Alanko I, Bhadane R, Bonvin AMJJ, Honorato RV, Hossain S, et al. Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development. *Processes*. 2020 Dec 30;9(1):71.
148. Zheng L, Meng J, Jiang K, Lan H, Wang Z, Lin M, et al. Improving protein–ligand docking and screening accuracies by incorporating a scoring function correction term. *Brief Bioinform*. 2022 May 13;23(3):bbac051.
149. Pradhan B, Bhattacharyya S, Pal K. IoT-Based Applications in Healthcare Devices. Fared MMS, editor. *J Healthc Eng*. 2021 Mar 18;2021:1–18.
150. Gao H, Yan C, Wu W, Li J. Application of Microfluidic Chip Technology in Food Safety Sensing. *Sensors*. 2020 Mar 24;20(6):1792.
151. McConnell EM, Nguyen J, Li Y. Aptamer-Based Biosensors for Environmental Monitoring. *Front Chem*. 2020 May 29;8:434.
152. Chandra P. Personalized biosensors for point-of-care diagnostics: from bench to bedside applications. *Nanotheranostics*. 2023;7(2):210–5.
153. Ngashangva L, Chattopadhyay S. Biosensors for point-of-care testing and personalized monitoring of gastrointestinal microbiota. *Front Microbiol*. 2023 May 5;14:1114707.
154. Clyde A, Galanie S, Kneller DW, Ma H, Babuji Y, Blaiszik B, et al. High-Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Noncovalent Inhibitor. *J Chem Inf Model*. 2022 Jan 10;62(1):116–28.
155. Badar MS, Shamsi S, Ahmed J, Alam MdA. Molecular Dynamics Simulations: Concept, Methods, and Applications. In: Rezaei N, editor. *Transdisciplinarity* [Internet]. Cham: Springer International Publishing; 2022 [cited 2023 May 31]. p. 131–51. (Integrated Science; vol. 5). Available from: https://link.springer.com/10.1007/978-3-030-94651-7_7
156. Bhalla N, Pan Y, Yang Z, Payam AF. Opportunities and Challenges for Biosensors and Nanoscale Analytical Tools for Pandemics: COVID-19. *ACS Nano*. 2020 Jul 28;14(7):7783–807.

157. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. *J Nanobiotechnology*. 2018 Dec;16(1):71.
158. Alahi MEE, Sukkuea A, Tina FW, Nag A, Kurdthongmee W, Suwannarat K, et al. Integration of IoT-Enabled Technologies and Artificial Intelligence (AI) for Smart City Scenario: Recent Advancements and Future Trends. *Sensors*. 2023 May 30;23(11):5206.
159. Malhotra BD, Ali MdA. Nanomaterials in Biosensors. In: *Nanomaterials for Biosensors* [Internet]. Elsevier; 2018 [cited 2023 May 31]. p. 1–74. Available from: <https://linkinghub.elsevier.com/retrieve/pii/B9780323449236000017>